A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer
Jimeno, A., Shirai, K., Choi, M., Laskin, J., Kochenderfer, M., Spira, A., Cline-Burkhardt, V., Winquist, E., Hausman, D., Walker, L., Cohen, R.B.
Published in Annals of oncology (01.03.2015)
Published in Annals of oncology (01.03.2015)
Get full text
Journal Article
Weekly paclitaxel, gemcitabine, and external irradiation followed by randomized farnesyl transferase inhibitor R115777 for locally advanced pancreatic cancer
Rich, Tyvin A, Winter, Kathryn, Safran, Howard, Hoffman, John P, Erickson, Beth, Anne, Pramila R, Myerson, Robert J, Cline-Burkhardt, Vivian Jm, Perez, Kimberly, Willett, Christopher
Published in OncoTargets and therapy (01.01.2012)
Published in OncoTargets and therapy (01.01.2012)
Get full text
Journal Article